AKAN
Akanda Corp.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · GB
$3.35
−8.72%Year over year
Reported trailing growth
- Revenue
- -77.1%
- EBITDA
- +52.2%
- EBIT
- +69.6%
- EPS
- +99.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -53.8%
- EBITDA
- —
- EBIT
- -13.7%
- Net income
- —
- EPS
- —
- Free cash flow
- -31.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025